"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...
– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
Maintenance therapy with azacitidine and valproic acid after allogeneic stem cell transplant in patients with high-risk myelodysplastic syndrome and acute myelogenous leukemia. QuANTUM-Wild: A phase 3 ...
Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Merin, director of the leukemia program at Cedars-Sinai ...
Therapeutic advances have significantly improved leukaemia survival rates, but this progress does not apply to all forms of the disease. Chronic myelomonocytic leukaemia (CMML) remains particularly ...
(RTTNews) - Cardiff Oncology, Inc. (CRDF) has presented new clinical data from an investigator-sponsored Phase 1 dose escalation trial evaluating onvansertib, a novel oral PLK1 inhibitor, in patients ...
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as ...
Leukemia in older adults causes symptoms like weight loss, fatigue, and night sweats. Your outlook depends on the type of leukemia you have. Leukemia is a type of cancer that affects the blood cells, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results